PMID- 30309639
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20181211
IS  - 1532-9461 (Electronic)
IS  - 1053-4296 (Linking)
VI  - 28
IP  - 4
DP  - 2018 Oct
TI  - A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) 
      for Liver Metastases in the Evolving Landscape of Oligometastatic Disease 
      Management.
PG  - 288-294
LID - S1053-4296(18)30054-7 [pii]
LID - 10.1016/j.semradonc.2018.06.009 [doi]
AB  - Metastases to the liver are common, and stereotactic body radiation therapy 
      (SBRT) is a recognized tool for ablation of liver metastases. Colorectal cancers 
      commonly metastasize to the liver, and long-term survival is possible after 
      metastasectomy. However, many patients are not candidates for surgical resection, 
      which opened the door to early studies investigating noninvasive techniques such 
      as liver SBRT. Multiple prospective trials have demonstrated excellent local 
      control with this approach coupled with an excellent safety record. The 
      oligometastatic disease state is now appreciated across many histologies, and 
      treatment of liver metastases as a component of oligometastatic disease 
      management has emerged as a rational and relevant strategy. To this end, recent 
      randomized studies in oligometastatic non-small-cell lung cancer demonstrated 
      improved progression-free survival with consolidative local therapy, and this 
      approach is the topic of ongoing cooperative group studies inclusive of patients 
      with an array of primary histologies. Further, there is a push to explore the 
      role of radiation as a means to enhance the efficacy of immune enabling drugs. 
      Recent prospective data evaluating the safety and response of SBRT with 
      anti-CTLA-4 therapy for patients with lung or liver metastasis demonstrated 
      clinical benefit (out of field immune-related partial response or immune-related 
      stable disease >/=6 months) in about a quarter of enrolled patients. Interestingly, 
      SBRT to liver metastases was found to elicit a greater systemic immune response 
      than SBRT to lung metastases. Classic management paradigms for metastatic disease 
      are rapidly being supplanted by approaches that are improving outcomes for 
      patients previously offered best supportive care or palliation alone. In this 
      article, we will review the established and emerging potential indications for 
      liver SBRT in this new era of oncologic care.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Robin, Tyler P
AU  - Robin TP
AD  - Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, 
      CO.
FAU - Raben, David
AU  - Raben D
AD  - Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, 
      CO.
FAU - Schefter, Tracey E
AU  - Schefter TE
AD  - Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, 
      CO. Electronic address: tracey.schefter@ucdenver.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Radiat Oncol
JT  - Seminars in radiation oncology
JID - 9202882
SB  - IM
MH  - Breast Neoplasms/pathology
MH  - Carcinoma, Non-Small-Cell Lung/pathology
MH  - Colorectal Neoplasms/pathology
MH  - Humans
MH  - Liver Neoplasms/*radiotherapy/*secondary
MH  - Lung Neoplasms/pathology
MH  - Prognosis
MH  - Progression-Free Survival
MH  - Radiosurgery/*methods
EDAT- 2018/10/13 06:00
MHDA- 2018/12/12 06:00
CRDT- 2018/10/13 06:00
PHST- 2018/10/13 06:00 [entrez]
PHST- 2018/10/13 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
AID - S1053-4296(18)30054-7 [pii]
AID - 10.1016/j.semradonc.2018.06.009 [doi]
PST - ppublish
SO  - Semin Radiat Oncol. 2018 Oct;28(4):288-294. doi: 10.1016/j.semradonc.2018.06.009.